Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2003

View Archived Issues

First patient enrolled in PRoFESS stroke prevention trial

Grants support work on ricin vaccine technology

Odyssey and Dharmacon investigate effects of siRNA-induced gene silencing

Aastrom receives SBIR grant for dendritic cell vaccine research

Access and Celltech enter oral drug delivery research collaboration

Tulobuterol tape found to induce no effects on the airway hyperresponsiveness of asthmatic children

Use of pregabalin in patients with partial seizures or pain

Ximelagatran prevents recurrence of cardiovascular events after myocardial infarction

Potential benefits described for KB-130015 in the treatment of atrial fibrillation

Reduced risk of cardiovascular death and MI reported for perindopril in stable coronary disease

Topical amitriptyline has analgesic effects in healthy volunteers

Limited activity described for exatecan mesilate as first-line monotherapy in NSCLC

Seasonale receives FDA approval

Japan Tobacco discontinues JTE-522 development

Arava launched in Japan

Acambis updates product development highlights

New agents with utility in urinary incontinence patented by Boehringer Ingelheim

Valproic acid analogues and their use in epilepsy and other disorders

New IgE production inhibitors in early development at Novartis

Pfizer reports preparation and testing of new ORL1 antagonists

New FAP-activated prodrugs of antitumor agents claimed by Boehringer Ingelheim

Novel glucocorticoid agonists and their use

Developments at Micrologix Biotech

Structurally novel vascular targeting agent discovered by Oxigene and Baylor U.

BMS-561389/DPC-906 as a phase II candidate for oral anticoagulant therapy

Promising new antifungal series presented by Genelabs at ICAAC meeting

GSQ-7302, a new SMAT with strong antipneumococcal activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...